Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency
Authors:
- 20 January 2016
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 174 (4) , 531-538
Abstract
Objective: Individuals with primary adrenal insufficiency (PAI) or congenital adrenal hyperplasia (CAH) receive life-long glucocorticoid (GC) replacement therapy. Current daily GC doses are still higher than the reported adrenal cortisol production rate. This GC excess could result in long-term morbidities such as osteoporosis. No prospective trials have investigated the long-term effect of GC dose changes in PAI and CAH patients.Methods: This is a prospective and longitudinal study including 57 subjects with PAI (42 women) and 33 with CAH (21 women). Bone mineral density (BMD) was measured by dual energy X-ray absorptiometry at baseline and after 2 years. Subjects were divided into three groups (similar baseline characteristics) depending on changes in daily hydrocortisone equivalent dose (group 1: unchanged 25.2±8.2 mg (mean±s.d.,n=50); group 2: increased 18.7±10.3 to 25.9±12.0 mg (n=13); group 3: decreased 30.8±8.5 to 21.4±7.2 mg (n=27)).Results: Subjects in group 1 showed normal lumbar and femoralZ-scores which were unchanged over time. Group 2 subjects showed a significant decrease in femoral neckZ-scores over time (−0.15±1.1 to −0.37±1.0 (PZ-scores (L1–L4: −0.93±1.2 to –0.65±1.5 (PP<0.05)). No changes in BMI over time were seen within any group. Reduction in GC dose did not increase the risk of adrenal crisis.Conclusion: This study demonstrates for the first time that cautious reduction in hydrocortisone equivalent doses leads to increases in BMD, whereas dose increments reduced BMD. These data emphasize the need for the lowest possible GC replacement dose in AI patients to maintain health and avoid long-term adverse effects.Keywords
This publication has 32 references indexed in Scilit:
- Bone Mineral Density Is Not Significantly Reduced in Adult Patients on Low-Dose Glucocorticoid Replacement TherapyThe Journal of Clinical Endocrinology & Metabolism, 2012
- Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on boneEuropean Journal of Endocrinology, 2009
- Long‐term follow‐up of bone mineral density in Addison's diseaseClinical Endocrinology, 2003
- Bone Mineral Density in Patients with Treated Addison's DiseaseOsteoporosis International, 1999
- Bone Mineral Density in Prepubertal and in Adolescent and Young Adult Patients With the Salt-wasting Form of Congenital Adrenal HyperplasiaPediatrics, 1997
- Bone turnover and bone mineral density in patients with congenital adrenal hyperplasiaClinical Endocrinology, 1996
- Effect of Glucocorticoid Replacement Therapy on Bone Mineral Density in Patients with Addison DiseaseAnnals of Internal Medicine, 1994
- Bone density and turnover in Addison's disease: effect of glucocorticoid treatmentBone and Mineral, 1994
- Daily Cortisol Production Rate in Man Determined by Stable Isotope Dilution/Mass SpectrometryThe Journal of Clinical Endocrinology & Metabolism, 1991
- Bone mineral density in Addison's disease: evidence for an effect of adrenal androgens on bone mass.BMJ, 1987